OncoSec Medical Inc (ONCS) Given a $6.00 Price Target at HC Wainwright

HC Wainwright set a $6.00 target price on OncoSec Medical Inc (NASDAQ:ONCS) in a research note issued to investors on Monday. The firm currently has a buy rating on the biotechnology company’s stock.

ONCS has been the subject of a number of other reports. Noble Financial restated a buy rating on shares of OncoSec Medical in a report on Sunday, March 19th. Maxim Group set a $5.00 price target on shares of OncoSec Medical and gave the stock a buy rating in a research report on Saturday, February 25th. Five analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and an average price target of $5.67.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical (NASDAQ:ONCS) traded up 0.2667% on Monday, reaching $0.9024. The company had a trading volume of 51,697 shares. The stock’s 50-day moving average price is $1.14 and its 200 day moving average price is $1.30. The firm’s market capitalization is $18.83 million. OncoSec Medical has a 52-week low of $0.88 and a 52-week high of $2.08.

TRADEMARK VIOLATION NOTICE: This piece was first reported by sleekmoney and is the property of of sleekmoney. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://sleekmoney.com/oncosec-medical-inc-oncs-given-a-6-00-price-target-at-hc-wainwright/1846585.html.

A hedge fund recently raised its stake in OncoSec Medical stock. Vanguard Group Inc. raised its position in OncoSec Medical Inc (NASDAQ:ONCS) by 34.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 564,106 shares of the biotechnology company’s stock after buying an additional 144,325 shares during the period. Vanguard Group Inc. owned approximately 2.70% of OncoSec Medical worth $722,000 at the end of the most recent quarter. 8.39% of the stock is currently owned by hedge funds and other institutional investors.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

12 Month Chart for NASDAQ:ONCS

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/oncosec-medical-inc-oncs-given-a-6-00-price-target-at-hc-wainwright/1846585.html

Receive News & Ratings for OncoSec Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *